Table 2 Clinical significance of miR-1-3p
Function | Effect | Sample | Notes | References |
|---|---|---|---|---|
Diagnostic marker | Distinguishing between benign and malignant OA | Plasma | The diagnostic significance is lower than that of tumor marker C125 | [150] |
Diagnostic marker | Diagnosing patients with STAD | Plasma | Combine with miR-125b-5p, miR-196a-5p, and miR-149-5p in serum | [151] |
Diagnostic marker | Diagnosing patients with CRC | Plasma | The predictive ability is better than CEA and CA211 | |
Prognostic marker | Predicting the risk of postoperative all-cause mortality in AAA patients | Plasma | / | [47] |
Prognostic marker | Predicting the risk of recurrence after radical resection in patients with Pca | Tissue | The only independent factor for prostate cancer recurrence | |
Prognostic marker | Evaluating the efficacy of intrathecal chemotherapy in patients with NSCLC-LM | Cerebrospinal fluid | / | [156] |
Toxicity marker | Evaluation of DOX-induced cardiotoxicity in the treatment of BC patients | Plasma | The ability to distinguish between patients with DOX-related myocardial injury and those without myocardial injury is superior to cTnI | [158] |